Show simple item record

dc.contributor.authorÇALıŞ, M
dc.contributor.authorPEKER, Ö
dc.contributor.authorEKIM, AA
dc.contributor.authorÖZGIRGIN, N
dc.contributor.authorÇEVIKOL, A
dc.contributor.authorRezvani, AYLİN
dc.contributor.authorINSTRUCT, Study
dc.contributor.authorİRDESEL, J
dc.contributor.authorŞENDUR, ÖF
dc.contributor.authorEYIGÖR, S
dc.contributor.authorAKARıRMAK, Ü
dc.contributor.authorKOÇYIĞIT, H
dc.contributor.authorESKIYURT, N
dc.contributor.authorESMAEILZADEH, S
dc.contributor.authorKURU, Ö
dc.contributor.authorYALÇINKAYA, EY
dc.date.accessioned2019-10-05T12:38:12Z
dc.date.available2019-10-05T12:38:12Z
dc.date.issued2016-08-01
dc.identifier
dc.identifier.citationAKARıRMAK Ü., KOÇYIĞIT H., ESKIYURT N., ESMAEILZADEH S., KURU Ö., YALÇINKAYA E., PEKER Ö., EKIM A., ÖZGIRGIN N., ÇALıŞ M., et al., -Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis.-, Acta orthopaedica et traumatologica turcica, cilt.50, ss.415-23, 2016
dc.identifier.urihttps://hdl.handle.net/20.500.12645/229
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197458/
dc.description.abstractObjective: In our study, we aimed to evaluate the influence of training on compliance and persistence with bisphosphonate treatment given on a weekly vs. monthly basis in postmenopausal osteoporosis patients. Methods: A total of 979 patients with postmenopausal osteoporosis (mean age: 63.2 ± 7.2 years) were included in this national, multicenter, prospective non-interventional observational cohort registry study. Patients were randomized into training (n ¼ 492, 50.3%, mean age: 63.4 ± 7.2 years) and control (n ¼ 487, 49.7%, mean age: 63.0 ± 7.1 years) groups. Patients in each intervention group were given weekly (44.9% and 44.6% for training and control subjects, respectively) or monthly (55.1% and 55.4%, respectively) bisphosphonate regimens. After the initial visit, patients were followed up at three-month intervals throughout 12 months of treatment for evaluation of persistence, compliance and adverse events. Results: On average, 79.4% of the patients were persistent with the treatment with a mean of 350.4 days of duration during the 12-month follow-up period. The mean compliance in the compliant and fully compliant group remained at an average of 86.6%. No significant difference was detected between the training and control groups in terms of compliance and persistence. Significantly longer persistence (360.0 ± 89.0 vs. 345.0 ± 108.0 days; p ¼ 0.035), higher percentage of persistent patients (83.4% vs. 74.2%; p ¼ 0.012) and higher compliance rates (88.8% vs. 83.3%; p ¼ 0.002) were noted in monthly regimen patients in comparison to those given weekly regimen. Conclusion: Our findings revealed remarkably high rates for persistence and compliance with bisphosphonate treatment in postmenopausal osteoporosis, with no impact of training on compliance and persistence rates. Longer persistence and better compliance rates were achieved with the monthly bisphosphonate regimen when compared to the weekly regimen.en
dc.language.isoen
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBisphosphonate
dc.subjectCompliance
dc.subjectDosing regimen
dc.subjectOsteoporosis
dc.subjectPersistence
dc.subjectTraining
dc.titleInfluence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis.
dc.typeArticle
local.avesis.response99
local.article.journalnameUrology journal
local.org.facultyTıp Fakültesi
dc.identifier.wosWOS:000384750400006
dc.identifier.scopus84994106436
dc.identifier.doi10.1016/j.aott.2016.07.001
dc.identifier.pubmed27524671
local.publication.isinternational1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record